Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

AGIO

Agios Pharmaceuticals Inc

Dec 26 • 04:00PM ET

34.37

Dollar change +0.18
Percentage change 0.53	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN REGN VRTX GILD ALNY SRPT NBIX BLUE FOLD NVAX

| Held by: VTI VB IWM VXF VBK XBI IWN VTWO IBB VHT

Scroll to Statements

Index	RUT	P/E	3.02	EPS (ttm)	11.37	Insider Own	3.32%	Shs Outstand	57.02M	Perf Week	-11.92%
Market Cap	1.96B	Forward P/E	-	EPS next Y	-6.13	Insider Trans	-3.18%	Shs Float	55.14M	Perf Month	-40.24%
Income	674.31M	PEG	-	EPS next Q	-1.69	Inst Own	104.72%	Short Float	9.28%	Perf Quarter	-28.47%
Sales	32.87M	P/S	59.63	EPS this Y	280.76%	Inst Trans	0.02%	Short Ratio	6.29	Perf Half Y	-21.19%
Book/sh	28.53	P/B	1.20	EPS next Y	-153.54%	ROA	48.18%	Short Interest	5.12M	Perf Year	49.43%
Cash/sh	17.62	P/C	1.95	EPS next 5Y	-	ROE	53.65%	52W Range	20.96 - 62.58	Perf YTD	54.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-0.98%	ROI	40.35%	52W High	-45.08%	Beta	0.80
Dividend TTM	-	Quick Ratio	8.77	Sales past 5Y	2.66%	Gross Margin	72.07%	52W Low	63.98%	ATR (14)	3.16
Dividend Ex-Date	-	Current Ratio	8.99	EPS Y/Y TTM	398.86%	Oper. Margin	-1238.10%	RSI (14)	27.98	Volatility	5.43% 7.79%
Employees	383	Debt/Eq	0.04	Sales Y/Y TTM	36.79%	Profit Margin	2051.38%	Recom	1.67	Target Price	57.71
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	1091.28%	Payout	-	Rel Volume	0.81	Prev Close	34.19
Sales Surprise	-4.64%	EPS Surprise	6.60%	Sales Q/Q	21.15%	Earnings	Oct 31 BMO	Avg Volume	813.22K	Price	34.37
SMA20	-26.07%	SMA50	-29.90%	SMA200	-18.59%	Trades		Volume	655,863	Change	0.53%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-10-24	Resumed	Raymond James	Outperform	$51
Sep-27-24	Downgrade	Leerink Partners	Outperform → Market Perform	$60 → $56
Feb-08-24	Initiated	Cantor Fitzgerald	Overweight
Feb-03-23	Initiated	Piper Sandler	Overweight	$41
Nov-17-22	Upgrade	Goldman	Sell → Neutral	$17 → $32
Jul-27-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$33
Dec-03-21	Initiated	BofA Securities	Buy	$54
Jul-30-21	Downgrade	Goldman	Neutral → Sell	$58 → $39
Jul-01-21	Initiated	Raymond James	Mkt Perform
Jun-10-21	Initiated	H.C. Wainwright	Buy	$88
Mar-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$50
Mar-01-21	Downgrade	JP Morgan	Overweight → Neutral	$64 → $54
Feb-26-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-22-20	Upgrade	Barclays	Equal Weight → Overweight	$46
Mar-04-20	Initiated	Barclays	Equal Weight	$50
Nov-26-19	Initiated	Cantor Fitzgerald	Overweight	$64
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy	$55
May-23-19	Resumed	Goldman	Neutral	$55
Feb-15-19	Upgrade	SVB Leerink	Mkt Perform → Outperform	$80

Show Previous Ratings

Dec-18-24 07:00AM	European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease (GlobeNewswire) -7.01%
Dec-10-24 09:39AM	Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank (TipRanks) -5.39%
Dec-09-24 04:21PM	Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug (Investor's Business Daily) -21.09%
Dec-08-24 12:40PM	Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat (GlobeNewswire)
Dec-05-24 08:42AM	Are Options Traders Betting on a Big Move in Agios (AGIO) Stock? (Zacks)
09:40AM	Loading…
Nov-26-24 09:40AM	Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-05-24 09:05AM	Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition (GlobeNewswire)
Nov-01-24 03:03AM	Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Oct-31-24 07:45AM	Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates (Zacks)
06:42AM	Agios Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Agios Reports Business Highlights and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-23-24 07:00AM	Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease (GlobeNewswire)
Oct-17-24 07:00AM	Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 (GlobeNewswire)
Sep-27-24 10:34AM	Do Options Traders Know Something About Agios (AGIO) Stock We Don't? (Zacks) -5.08%
Sep-26-24 04:05PM	Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. (Investor's Business Daily)
07:56AM	Loading…
Sep-17-24 07:56AM	Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results (Insider Monkey)
Sep-12-24 06:33AM	Agios Pharmaceuticals tebapivat gains FDA orphan drug designation (Pharmaceutical Technology)
Sep-11-24 07:00AM	Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS) (GlobeNewswire)
Sep-05-24 07:00AM	Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024 (GlobeNewswire)
Aug-09-24 07:50AM	Agios Pharmaceuticals, Inc. (AGIO): Are Street Analysts Bullish on This Top Caligan Partner Holding Right Now? (Insider Monkey)
07:23AM	Is Agios Pharmaceuticals, Inc. (AGIO) a Good Addition to Your Portfolio Now? (Insider Monkey)
Aug-06-24 05:50PM	Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib (GlobeNewswire)
Aug-01-24 01:42PM	Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides (Benzinga)
07:45AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:43AM	Agios Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
06:31AM	Agios Reports Business Highlights and Second Quarter 2024 Financial Results (GlobeNewswire)
06:30AM	Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused (GlobeNewswire)
Jul-25-24 10:01AM	Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-18-24 07:00AM	Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024 (GlobeNewswire)
Jun-24-24 04:25AM	Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains? (Zacks)
08:45AM	Loading…
Jun-15-24 08:45AM	Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress (GlobeNewswire)
Jun-07-24 07:00PM	Insider Sale: CEO Brian Goff Sells Shares of Agios Pharmaceuticals Inc (AGIO) (GuruFocus.com)
Jun-06-24 09:00AM	Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET (GlobeNewswire)
Jun-05-24 06:14AM	June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge (InvestorPlace)
Jun-04-24 12:44PM	Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study (Zacks) +8.03%
Jun-03-24 06:30AM	Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia (GlobeNewswire) +20.61%
May-30-24 04:05PM	Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 (GlobeNewswire)
May-29-24 12:35PM	Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty (Zacks)
May-28-24 04:03PM	Agios Breaks Out On 'Buffed Up' Financials After Inking Massive Brain Cancer Deal (Investor's Business Daily) +23.21%
12:20PM	Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 (Associated Press Finance)
09:46AM	Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out (Investor's Business Daily)
08:12AM	Agios cashes in on cancer drug again with $905M Royalty Pharma deal (BioPharma Dive)
07:00AM	Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty (GlobeNewswire)
May-24-24 09:55AM	How Much Upside is Left in Agios Pharmaceuticals (AGIO)? Wall Street Analysts Think 26.43% (Zacks)
May-14-24 10:00AM	Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress (GlobeNewswire)
May-08-24 09:55AM	Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High? (Zacks)
May-06-24 07:00AM	Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024 (GlobeNewswire)
May-03-24 12:21PM	Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates (Zacks)
11:10AM	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:00AM	Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024 (GlobeNewswire)
03:03AM	Agios Pharmaceuticals Inc (AGIO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-02-24 10:45PM	Q1 2024 Agios Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
12:57PM	Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss (MT Newswires)
11:56AM	AGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:44AM	Agios Pharmaceuticals Reports Q1 2024 Earnings: Narrower Loss than Expected with Strong Revenue ... (GuruFocus.com)
08:25AM	Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:29AM	Agios Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Agios Reports Business Highlights and First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 10:02AM	Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-18-24 07:00AM	Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024 (GlobeNewswire)
Apr-16-24 04:30PM	The 3 Best Biotech Stocks to Buy Now: Q2 Edition (InvestorPlace)
Apr-10-24 07:01PM	Director Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO) (GuruFocus.com)
Apr-09-24 07:00AM	Agios Publishes 2024 Environmental, Social and Governance (ESG) Report (GlobeNewswire) +7.26%
Mar-05-24 07:00AM	Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024 (GlobeNewswire)
Feb-26-24 03:12PM	Agios Pharmaceuticals Stock Earns IBD Stock Upgrade Again, Hitting 90-Plus RS Rating (Investor's Business Daily)
Feb-23-24 10:45AM	Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark (Investor's Business Daily) +10.78%
Feb-22-24 07:00AM	Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024 (GlobeNewswire) +11.12%
Feb-20-24 08:24AM	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-16-24 09:38AM	Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates (Zacks)
Feb-15-24 10:15PM	Q4 2023 Agios Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
08:25AM	Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:59AM	Agios Pharmaceuticals Inc (AGIO) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
07:00AM	Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-08-24 10:00AM	Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline (Zacks)
Feb-02-24 07:00AM	Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024 (GlobeNewswire)
Jan-24-24 07:02PM	Agios Pharmaceuticals Inc Director Jacqualyn Fouse Sells 10,722 Shares (GuruFocus.com) +8.88%
Jan-11-24 07:15PM	Insider Sell: CEO Brian Goff Sells 12,066 Shares of Agios Pharmaceuticals Inc (AGIO) (GuruFocus.com)
Jan-08-24 07:00AM	Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio (GlobeNewswire) +5.66%
Jan-04-24 11:19AM	Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study (Zacks)
07:47AM	Agios Pharmaceuticals (AGIO) Soars 5.2%: Is Further Upside Left in the Stock? (Zacks)
Jan-03-24 04:05PM	Agios Stock Whipsaws As It Looks To Rival Crispr, Vertex In A Key Market (Investor's Business Daily) +5.21%
02:46PM	Biotech Stocks Dyne, Agios Leap on Muscle-Disorder Drugs' Trial Results (The Wall Street Journal)
02:01PM	Biotechs Dyne, Agios Leap on Muscle-Disorder Drugs Trial Results (The Wall Street Journal)
10:09AM	Agios Pharma Surged, And Then Pulled Back, After Testing A Thalassemia Drug (Investor's Business Daily)
09:26AM	Agios Pharma Surges, And Retakes Its 200-Day Line, On Promising Test Results For Thalassemia Drug (Investor's Business Daily)
06:58AM	Midday movers: Apple, Tesla, Eli Lilly and more (Investing.com)
06:40AM	Agios' blood disorder drug meets goals of late-stage study (Reuters)
06:30AM	Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (GlobeNewswire)
Jan-02-24 07:00AM	Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 (GlobeNewswire)
Dec-09-23 07:00PM	Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition (GlobeNewswire)
Nov-21-23 10:56AM	Agios (AGIO) Meets Clinical Proof-of-Concept in Anemia Treatment (Zacks)
Nov-20-23 07:00AM	Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes (GlobeNewswire)
Nov-03-23 12:10PM	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2023 Earnings Call Transcript (Insider Monkey) +7.10%
11:06AM	Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales (Zacks)
Nov-02-23 09:32AM	Agios Pharmaceuticals Inc (AGIO) Reports Q3 2023 Earnings, Reveals 10% Increase in U.S. Net Revenue (GuruFocus.com)
09:05AM	Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition (GlobeNewswire)
07:10AM	Agios Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Agios Reports Business Highlights and Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-19-23 07:00AM	Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023 (GlobeNewswire)
Sep-07-23 11:30AM	Why Is Haemonetics (HAE) Down 1.9% Since Last Earnings Report? (Zacks)

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Scadden David	Director	Dec 11 '24	Option Exercise	18.09	200	3,618	15,683	Dec 13 04:04 PM
Scadden David	Director	Dec 11 '24	Sale	46.28	200	9,256	15,483	Dec 13 04:04 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Nov 08 '24	Sale	56.09	772	43,301	813	Nov 13 04:14 PM
Ballal Rahul D.	Director	Nov 07 '24	Option Exercise	25.99	10,000	259,900	17,992	Nov 12 04:09 PM
Ballal Rahul D.	Director	Nov 08 '24	Option Exercise	25.99	10,000	259,900	17,992	Nov 12 04:09 PM
Ballal Rahul D.	Director	Nov 08 '24	Sale	58.19	10,000	581,911	7,992	Nov 12 04:09 PM
Ballal Rahul D.	Director	Nov 07 '24	Sale	53.52	10,000	535,236	7,992	Nov 12 04:09 PM
Burns James William	Chief Legal Officer	Nov 07 '24	Sale	52.21	21,752	1,135,775	15,700	Nov 12 04:08 PM
RAHUL BALLAL	Director	Nov 08 '24	Proposed Sale	58.19	10,000	581,894		Nov 08 04:17 PM
RAHUL BALLAL	Director	Nov 07 '24	Proposed Sale	53.52	10,000	535,241		Nov 07 04:51 PM
JAMES BURNS	Officer	Nov 07 '24	Proposed Sale	52.21	21,752	1,135,711		Nov 07 04:06 PM
Jones Cecilia	Chief Financial Officer	Sep 26 '24	Option Exercise	0.00	7,473	0	22,700	Sep 30 04:15 PM
Jones Cecilia	Chief Financial Officer	Sep 26 '24	Sale	49.03	2,542	124,634	20,158	Sep 30 04:15 PM
Ballal Rahul D.	Director	Aug 11 '24	Option Exercise	0.00	2,302	0	7,992	Aug 13 04:15 PM
Smith Cynthia	Director	Aug 11 '24	Option Exercise	0.00	2,302	0	7,992	Aug 13 04:12 PM
Goff Brian	Chief Executive Officer	Aug 08 '24	Option Exercise	0.00	22,691	0	89,883	Aug 12 05:15 PM
Goff Brian	Chief Executive Officer	Aug 08 '24	Sale	42.75	11,091	474,140	78,792	Aug 12 05:15 PM
Goff Brian	Officer	Aug 08 '24	Proposed Sale	42.75	11,091	474,184		Aug 08 04:08 PM
Gheuens Sarah	Chief Medical Officer	Jul 01 '24	Option Exercise	0.00	8,375	0	47,441	Jul 03 04:30 PM
Gheuens Sarah	Chief Medical Officer	Jul 01 '24	Sale	43.85	3,705	162,464	43,736	Jul 03 04:30 PM
Foster-Cheek Kaye I	Director	Jun 13 '24	Option Exercise	0.00	3,388	0	8,912	Jun 17 05:32 PM
FOUSE JACQUALYN A	Director	Jun 13 '24	Option Exercise	0.00	3,388	0	140,784	Jun 17 05:31 PM
Schenkein David P	Director	Jun 13 '24	Option Exercise	0.00	3,388	0	126,242	Jun 17 05:29 PM
Ballal Rahul D.	Director	Jun 13 '24	Option Exercise	0.00	3,388	0	5,690	Jun 17 05:22 PM
Smith Cynthia	Director	Jun 13 '24	Option Exercise	0.00	3,388	0	5,690	Jun 17 05:20 PM
Ho Maykin	Director	Jun 13 '24	Option Exercise	0.00	3,388	0	14,912	Jun 17 05:19 PM
Scadden David	Director	Jun 13 '24	Option Exercise	0.00	3,388	0	15,483	Jun 17 05:18 PM
Owen Catherine E.	Director	Jun 13 '24	Option Exercise	0.00	1,976	0	1,976	Jun 17 05:15 PM
CAPELLO JEFFREY D	Director	Jun 13 '24	Option Exercise	0.00	1,976	0	1,976	Jun 17 05:13 PM
Goff Brian	Chief Executive Officer	Jun 05 '24	Option Exercise	0.00	25,527	0	79,307	Jun 07 04:25 PM
Goff Brian	Chief Executive Officer	Jun 05 '24	Sale	48.84	12,115	591,697	67,192	Jun 07 04:25 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Jun 03 '24	Sale	44.39	1,362	60,459	1,524	Jun 05 04:14 PM
FOUSE JACQUALYN A	Director	Apr 08 '24	Option Exercise	0.00	15,934	0	145,187	Apr 10 04:03 PM
FOUSE JACQUALYN A	Director	Apr 10 '24	Sale	27.55	7,791	214,642	137,396	Apr 10 04:03 PM
Foster-Cheek Kaye I	Director	Mar 07 '24	Sale	31.62	1,285	40,632	5,524	Mar 11 04:09 PM
Foster-Cheek Kaye I	Director	Mar 06 '24	Sale	31.99	4,415	141,236	6,809	Mar 07 06:49 PM
Foster-Cheek Kaye I	Director	Mar 05 '24	Sale	32.21	300	9,663	11,224	Mar 07 06:49 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 05 '24	Sale	31.75	1,913	60,738	2,886	Mar 07 06:47 PM
Gheuens Sarah	Chief Medical Officer	Mar 01 '24	Option Exercise	0.00	7,834	0	40,415	Mar 05 04:20 PM
Gheuens Sarah	Chief Medical Officer	Mar 05 '24	Sale	32.57	2,642	86,050	36,415	Mar 05 04:20 PM
Jones Cecilia	Chief Financial Officer	Mar 01 '24	Option Exercise	0.00	2,000	0	15,512	Mar 05 04:18 PM
Jones Cecilia	Chief Financial Officer	Mar 05 '24	Sale	32.57	672	21,887	14,840	Mar 05 04:18 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 01 '24	Option Exercise	0.00	3,127	0	5,718	Mar 05 04:15 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 05 '24	Sale	32.57	1,214	39,540	3,368	Mar 05 04:15 PM
Goff Brian	Chief Executive Officer	Mar 01 '24	Option Exercise	0.00	8,500	0	57,936	Mar 05 04:10 PM
Goff Brian	Chief Executive Officer	Mar 05 '24	Sale	32.57	4,156	135,361	53,780	Mar 05 04:10 PM
Burns James William	Chief Legal Officer	Mar 01 '24	Option Exercise	0.00	7,834	0	38,518	Mar 05 04:08 PM
Burns James William	Chief Legal Officer	Mar 05 '24	Sale	32.57	2,642	86,050	34,518	Mar 05 04:08 PM
Schenkein David P	Director	Feb 27 '24	Option Exercise	31.64	69,329	2,193,570	180,325	Feb 29 04:05 PM
Schenkein David P	Director	Feb 27 '24	Sale	34.67	69,329	2,403,592	122,854	Feb 29 04:05 PM
Schenkein David P	Director	Feb 23 '24	Option Exercise	31.64	47,731	1,510,209	170,585	Feb 27 04:04 PM
Schenkein David P	Director	Feb 26 '24	Option Exercise	31.64	20,411	645,804	143,265	Feb 27 04:04 PM
Schenkein David P	Director	Feb 23 '24	Sale	33.05	47,731	1,577,510	122,854	Feb 27 04:04 PM
Schenkein David P	Director	Feb 26 '24	Sale	33.19	20,411	677,441	122,854	Feb 27 04:04 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 20 '24	Sale	26.63	504	13,422	2,741	Feb 22 05:43 PM
Gheuens Sarah	Chief Medical Officer	Feb 12 '24	Option Exercise	0.00	2,162	0	34,073	Feb 14 05:53 PM
Gheuens Sarah	Chief Medical Officer	Feb 14 '24	Sale	25.14	642	16,140	33,431	Feb 14 05:53 PM
Burns James William	Chief Legal Officer	Feb 12 '24	Option Exercise	0.00	1,833	0	32,211	Feb 14 05:51 PM
Burns James William	Chief Legal Officer	Feb 14 '24	Sale	25.14	545	13,701	31,666	Feb 14 05:51 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 12 '24	Option Exercise	0.00	777	0	3,518	Feb 14 05:50 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 14 '24	Sale	25.14	273	6,863	3,245	Feb 14 05:50 PM
Burns James William	Chief Legal Officer	Jan 20 '24	Option Exercise	0.00	5,750	0	32,086	Jan 24 04:25 PM
Burns James William	Chief Legal Officer	Jan 24 '24	Sale	21.64	1,708	36,961	30,378	Jan 24 04:25 PM
Gheuens Sarah	Chief Medical Officer	Jan 20 '24	Option Exercise	0.00	5,750	0	33,619	Jan 24 04:24 PM
Gheuens Sarah	Chief Medical Officer	Jan 24 '24	Sale	21.64	1,708	36,961	31,911	Jan 24 04:24 PM
Jones Cecilia	Chief Financial Officer	Jan 20 '24	Option Exercise	0.00	5,380	0	14,955	Jan 24 04:23 PM
Jones Cecilia	Chief Financial Officer	Jan 24 '24	Sale	21.64	1,886	40,813	13,069	Jan 24 04:23 PM
FOUSE JACQUALYN A	Director	Jan 20 '24	Option Exercise	0.00	23,900	0	139,975	Jan 24 04:22 PM
FOUSE JACQUALYN A	Director	Jan 24 '24	Sale	21.64	10,722	232,024	129,253	Jan 24 04:22 PM
Goff Brian	Chief Executive Officer	Jan 20 '24	Option Exercise	0.00	17,018	0	57,071	Jan 24 04:20 PM
Goff Brian	Chief Executive Officer	Jan 24 '24	Sale	21.64	7,635	165,221	49,436	Jan 24 04:20 PM
Milanova Tsveta	Chief Commercial Officer	Jan 20 '24	Option Exercise	0.00	5,448	0	14,852	Jan 24 04:19 PM
Milanova Tsveta	Chief Commercial Officer	Jan 24 '24	Sale	21.64	1,618	35,014	13,234	Jan 24 04:19 PM
Goff Brian	Chief Executive Officer	Jan 05 '24	Option Exercise	0.00	25,527	0	52,119	Jan 09 04:28 PM
Goff Brian	Chief Executive Officer	Jan 09 '24	Sale	22.99	12,066	277,397	40,053	Jan 09 04:28 PM
FOUSE JACQUALYN A	Director	Jan 05 '24	Option Exercise	0.00	17,500	0	124,466	Jan 09 04:26 PM
FOUSE JACQUALYN A	Director	Jan 09 '24	Sale	22.99	8,391	192,909	116,075	Jan 09 04:26 PM
Burns James William	Chief Legal Officer	Jan 05 '24	Option Exercise	0.00	3,250	0	27,499	Jan 09 04:25 PM
Burns James William	Chief Legal Officer	Jan 09 '24	Sale	22.99	1,163	26,737	26,336	Jan 09 04:25 PM
Gheuens Sarah	Chief Medical Officer	Jan 05 '24	Option Exercise	0.00	5,000	0	29,658	Jan 09 04:22 PM
Gheuens Sarah	Chief Medical Officer	Jan 09 '24	Sale	22.99	1,789	41,129	27,869	Jan 09 04:22 PM
Milanova Tsveta	Chief Commercial Officer	Jan 03 '24	Option Exercise	0.00	8,475	0	12,306	Jan 05 04:10 PM
Milanova Tsveta	Chief Commercial Officer	Jan 05 '24	Sale	22.32	2,902	64,773	9,404	Jan 05 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AGIO

Agios Pharmaceuticals Inc

Upgrade your FINVIZ experience